Phase 2 Ovarian Cancer Trial, Not Yet Recruiting NCT06600841 Sponsor: Fujian Cancer Hospital Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Not Yet Recruiting

NCT06600841
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 18 to 70 years old who are female.
  • People who have been diagnosed through laboratory testing (including biopsy) with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, where the cancer came back within less than six months after completing a chemotherapy treatment that contained platinum.
  • People who have at least one area of cancer that can be measured using standard imaging guidelines (called RECIST 1.1).
  • People who have a confirmed mutation in a gene related to DNA repair (called an HRR gene mutation), found through testing of a tissue or blood sample.
  • People with a performance status score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor limitations in physical activity.
  • People whose blood counts and organ function results meet specific normal ranges, including healthy levels of haemoglobin, white blood cells, platelets, liver enzymes, bilirubin, and kidney function (confirm specific values with trial site).
  • People whose blood clotting test results (APTT, PT, and INR) are within acceptable ranges, or within the expected range if already taking blood thinners.
  • People without serious heart, lung, liver, or kidney conditions.
  • Women who could become pregnant must have a negative pregnancy blood test within 7 days before joining, and must agree to use suitable contraception during the trial and for 8 weeks after the last dose of the study drug.
  • People with an estimated life expectancy of at least 12 weeks.
  • People who are willing and able to sign a consent form and follow the trial visit schedule and procedures.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are currently participating in another clinical trial using a different experimental drug at the same time.
  • People with a known allergy or sensitivity to fluzoparib or to any ingredient in drugs with a similar chemical structure.
  • People with a known allergy or sensitivity to adebrelimab or to any ingredient in drugs with a similar chemical structure.
  • People who are unable to swallow tablets or capsules, or who have gut problems that could affect how the study drugs are absorbed, such as uncontrolled nausea or vomiting, bowel obstruction, or malabsorption.
  • People who have previously been treated with immune checkpoint inhibitor drugs (a type of cancer immunotherapy).
  • People who have an active autoimmune disease or a history of autoimmune disease (such as lung inflammation, eye inflammation, bowel inflammation, liver inflammation, or thyroid and other immune-related conditions) — though people with vitiligo or childhood asthma or allergies that no longer need treatment may still be considered (confirm with trial site).
  • People with autoimmune-related underactive thyroid who are on a stable dose of thyroid replacement medication, or people with Type 1 diabetes on a stable dose of insulin (confirm with trial site).
  • People with a history of immune system deficiency, a positive HIV test, other inherited or acquired immune disorders, or a history of organ transplant or bone marrow transplant from a donor.
  • People with unstable conditions such as high blood pressure that cannot be controlled with medication (systolic at or above 140 mmHg or diastolic at or above 90 mmHg), or serious irregular heart rhythms.
  • People with a history of, or currently having, certain lung conditions such as pulmonary fibrosis, interstitial lung disease, dust-related lung disease, radiation-related lung inflammation, organising pneumonia, drug-related lung inflammation, or active pneumonia seen on a CT scan during screening.
  • People with significant heart problems that are not well controlled, including heart failure above a certain severity level, unstable chest pain (angina), a heart attack within the past year, serious heart rhythm problems requiring treatment, or a specific heart electrical measurement (QTc) above 470ms.
  • People who are pregnant, breastfeeding, or planning to become pregnant during the study treatment period.
  • People whom the trial investigators consider unsuitable for participation for other reasons.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026

Contact this trial

Phone: 15959028989

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Fujian Cancer Hospital
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
1 March 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate(ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov